Position in JANX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$686,423
+$114,510 QoQ
Shares Held
49,383
+19.2% QoQ
Ownership
0.081%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HighVista Strategies LLC holds $224,607,258 across 76 Biotechnology names. JANX ranks #68 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
113,254 | $12,610,832 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
26,323 | $8,481,007 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
197,051 | $7,584,492 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
146,264 | $7,377,556 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
124,647 | $7,243,237 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
69,309 | $6,740,300 | |
| 7 | TERN |
Terns Pharmaceuticals, Inc.
|
114,307 | $6,026,265 | |
| 8 | GPCR |
Structure Therapeutics Inc.
|
123,909 | $5,972,413 |
All Filings in JANX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $686,423 | 49,383 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $571,913 | 41,443 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,350,310 | 55,250 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,442,271 | 62,436 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $2,013,012 | 74,556 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,732,541 | 69,715 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $1,066,332 | 23,472 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $977,377 | 23,332 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||